Loading...
XSTO
FLUI
Market cap1mUSD
Apr 11, Last price  
12.22SEK
1D
-3.63%
1Q
22,869.92%
IPO
-32.98%
Name

Fluicell AB

Chart & Performance

D1W1MN
P/E
—
P/S
5.03
EPS
—
Div Yield, %
—
Shrs. gr., 5y
68.07%
Rev. gr., 5y
22.18%
Revenues
3m
+2.68%
140,2681,415,8102,635,0001,052,0001,226,0002,488,0004,635,0002,602,0003,251,0003,338,000
Net income
-27m
L+23.58%
-1,646,881-3,783,421-4,950,000-7,470,000-14,700,000-18,635,000-18,154,000-21,720,000-21,487,000-26,554,000
CFO
-27m
L+29.39%
00-5,497,000-7,831,000-12,462,000-17,069,000-17,569,000-18,640,000-21,043,000-27,227,000

Profile

Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.
URL
https://fluicell.com/
IPO date
Apr 18, 2018
Employees
20
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,338
2.68%
3,251
24.94%
Cost of revenue
1,600
663
Unusual Expense (Income)
NOPBT
1,738
2,588
NOPBT Margin
52.07%
79.61%
Operating Taxes
(120)
Tax Rate
NOPAT
1,738
2,708
Net income
(26,554)
23.58%
(21,487)
-1.07%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,871
25,942
BB yield
-5.46%
-14.74%
Debt
Debt current
(1,014)
Long-term debt
Deferred revenue
Other long-term liabilities
858
Net debt
(2,763)
(25,471)
Cash flow
Cash from operating activities
(27,227)
(21,043)
CAPEX
(1,136)
Cash from investing activities
(1,136)
Cash from financing activities
5,533
25,942
FCF
2,737
2,242
Balance
Cash
2,763
24,457
Long term investments
Excess cash
2,596
24,294
Stockholders' equity
(136,251)
(109,997)
Invested Capital
136,676
129,908
ROIC
1.30%
2.30%
ROCE
408.94%
13.00%
EV
Common stock shares outstanding
112,158
67,696
Price
0.63
-75.69%
2.60
-87.06%
Market cap
70,884
-59.73%
176,009
-85.21%
EV
68,121
150,538
EBITDA
2,348
3,308
EV/EBITDA
29.01
45.51
Interest
30
238
Interest/NOPBT
1.73%
9.20%